PepGen Inc
NASDAQ:PEPG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hangzhou Kelin Electric Co Ltd
SSE:688611
|
CN |
|
L
|
Lee & Man Paper Manufacturing Ltd
HKEX:2314
|
HK |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (13.3), the stock would be worth $73.24 (4 134% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.3 | $1.73 |
0%
|
| Industry Average | 13.3 | $73.24 |
+4 134%
|
| Country Average | 14.4 | $79.06 |
+4 470%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$218.3m
|
/ |
Jan 2026
$-92.2m
|
= |
|
|
$218.3m
|
/ |
Dec 2026
$-105.8m
|
= |
|
|
$218.3m
|
/ |
Dec 2027
$-134m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
PepGen Inc
NASDAQ:PEPG
|
119.2m USD | 0.3 | -1.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.1B USD | 14.3 | 86 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.7B USD | 14.2 | 24.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
168.6B USD | 12.4 | 19.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.5B USD | 21.2 | 28.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 13 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.8B EUR | 42.6 | 39.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 10.9 | 32.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
PepGen Inc
Glance View
PepGen Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2022-05-06. PepGen Inc. is a clinical-stage biotechnology company advancing the oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotides (EDOs) are designed to target the underlying causes of rare genetic diseases, such as duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The firm through its enhanced delivery oligonucleotide (EDO) platform developing a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates to treat a variety of degenerative neuromuscular diseases. Its lead product candidates include PGN-EDO51 and PGN-EDODM1. Its lead product candidate PGN-EDO51, is an EDO peptide conjugated to a phosphorodiamidate morpholino oligomer (PMO) therapeutic cargo, which is developed for the treatment of DMD patients with mutations amenable to exon 51-skipping approach. The firm is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, for the treatment of DM1.
